INDUCTION AND DETECTION OF A HUMAN ENDOTHELIAL ACTIVATION ANTIGEN IN VIVO

BY RAMZI S. COTRAN, MICHAEL A. GIMBRONE, JR., MICHAEL P. BEVILACQUA, DONNA L. MENDRICK, AND JORDAN S. POBER

From the Department of Pathology, Brigham and Women's Hospital; and Harvard Medical School, Boston, Massachusetts 02115

Considerable evidence now supports an active role for vascular endothelial cells in the initiation of inflammatory and immunological responses, including adhesion of circulating leukocytes, stimulation of intravascular coagulation, and presentation of antigen to T cells. In previous studies (1–4), we have shown that some of these endothelial effects can be induced in vitro by well-defined monokines, lymphokines, and other stimuli. In particular, IL-1, tumor necrosis factor (TNF), and bacterial LPS stimulate the synthesis and surface expression of a tissue factor–like procoagulant activity in cultured human endothelial cells (1, 2) and increase endothelial adhesivity for leukocytes (3, 4). Similar results have been reported by others (5, 6). These inducible functions are dependent on protein and RNA synthesis, are maximal 4–6 h after exposure to the monokines, and decline by 24 h (4). We recently reported (7) that both IL-1 and TNF also induce the expression of a new endothelial cell surface protein, identified by specific binding to an mAb, H4/18, which had been developed by immunization with IL-1-treated endothelial cells. The time sequence of induction of the H4/18 binding antigen and its susceptibility to metabolic inhibitors were similar to those observed for increased procoagulant activity and leukocyte adhesion, suggesting that H4/18 binding could be a useful marker for these inducible endothelial functions.

Using immunocytochemical techniques, we now report that the H4/18 binding antigen can be induced in microvascular endothelium of human skin in delayed hypersensitivity reactions (DHR), and that it can be detected in a variety of human inflammatory conditions with an immune background. These studies indicate that H4/18 is a useful marker for activated endothelium in situ, and lend credence to the relevance of inducible endothelial functions initially observed in vitro, to inflammation in vivo.

Materials and Methods

mAbs and Immunohistochemical Techniques. mAb H4/18, developed by immunizing BALB/c mice with cultured human umbilical vein endothelial cells (HEC) pretreated for 4 h with 5 U/ml of affinity-purified human IL-1, has been described previously (7). H4/18

This work was supported by National Institutes of Health grants HL-22602 and HL-36008. J. S. Pober is an Established Investigator of the American Heart Association. Address correspondence to Dr. Ramzi S. Cotran, Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115

J. Exp. Med. © The Rockefeller University Press · 0022-1007/86/08/0661/06 $1.00
Volume 164 · August 1986 · 661–666
was detected by immunoperoxidase screening of binding to IL-1-treated vs. control HEC; the antibody is of the IgG1K isotype. For the present study, the antibody was used as the culture supernatant, diluted in 10% horse serum to a concentration of ~0.05 mg/ml of mouse Ig. In some experiments, F(ab')2 fragments of antibody were prepared from ascites fluid (8) and reconstituted to ~3.4 mg/ml.

For immunohistochemical studies, tissues were frozen in isopentane liquid nitrogen; 4–6 μm frozen sections were fixed in acetone for 10 min, washed three times in PBS, and incubated for either 1 h at room temperature or occasionally overnight at 4°C with optimally diluted mAbs. Sections were then washed and incubated with peroxidase-conjugated rabbit anti-mouse IgG (Dako Corp., Santa Barbara, CA), diluted in PBS containing 20% normal human serum for 30–60 min. Peroxidase activity was detected using either diaminobenzidine (DAB, 6 mg/ml in 0.1 M Tris/saline buffer at pH 7.6 with 0.03% H2O2), or acetylthio-carbazol (AEC, 0.02% in 5% dimethyl formamide, 0.2% sodium acetate buffer, pH 5, with 0.03% H2O2) containing reaction mixtures. The sections were then washed in distilled water, lightly post-stained with hematoxylin, and mounted.

Control antibody was routinely tested on step sections of the same tissue specimens. The control used was an irrelevant IgG1K supernatant, K16/16. Six other control antibodies prepared against rat renal structures, and having the same isotype and Ig concentration, were tested on selected specimens. Step sections were also stained with anti-von Willebrand factor (anti-vWF) mAb (Cappel Laboratories, Cochranville, PA); these served as positive controls for normal endothelial staining.

Delayed Hypersensitivity Reactions. Two sets of DHR were elicited on forearm skin of a healthy male volunteer using streptococcal varidase (Lederle, The Netherlands, B.V.; containing 100,000 IU/ml of streptokinase and 25,000 IU/ml of streptodornase) as antigen. In the first study, the streptococcal varidase reaction site, an area of erythema and induration ~35 mm in diameter, was biopsied under local anaesthesia at 23 h. In the second study, a control punch biopsy was obtained, and immediately thereafter 0.1 ml of varidase was injected intracutaneously in two sites. At 16 h, both sites were strongly reactive, with erythema and induration measuring 35 mm in diameter. One of the two sites was biopsied at 16 h, and the second at 6 days, when the induration and erythema had largely disappeared.

Tissues. A variety of normal and pathologic tissues (see Results) were selected from fresh surgical specimens or from a bank of frozen tissue in the Department of Pathology at the University of Leiden School of Medicine, The Netherlands, or at the Brigham and Women's Hospital. In addition to the immunohistochemical studies, representative sections were stained with hematoxylin and eosin, and other special stains as required, and most of the lymph nodes were subjected to immunophenotypic analysis of lymphoid cells, using commercially available antisera (9).

Results

Normal Tissues. There was no staining in H4/18 antibody in the microvascular endothelium (arterioles, capillaries, and venules) of the following normal tissues examined: skin (chest, arm, abdomen, neck); kidney; heart; skeletal muscle; liver; spleen; ovaries; lung; or subcutaneous fat. Four normal lymph nodes were also negative. One lymph node obtained from a lymph node dissection for prostatic carcinoma showed fine specks of positive staining along the vascular endothelium of postcapillary venules. In some skin sections, there was focal staining of squamous epithelium and eccrine duct epithelium. When the same tissues were stained with anti-vWF antibody, there was the expected strong staining of normal endothelial cells. Attempts to increase the sensitivity of the immunoperoxidase-labeling technique including the avidin-biotin procedure (10), did not uncover endothelial staining in the normal tissues.

Delayed Hypersensitivity Reactions. As expected from the initial screening of
normal skin, the control punch biopsy showed no endothelial staining with the mAb H4/18. In contrast, the well-developed hypersensitivity reaction sites, at 16 and 23 h, exhibited strong reaction product in numerous small vessels in the hypodermis and dermis (Fig. 1). The staining outlined the vessel lumens, and on high magnification (Fig. 2) appeared to be exclusively in endothelium; it was most prominent in the deeper venules exhibiting a dense perivascular infiltrate,
but was also present in the more superficial smaller vessels. The reaction product was granular in both DAB- and in the AEC-reacted slides. Except for endogenous peroxidase in polymorphonuclear leukocytes (present also in sections stained with control antibodies), there was no staining of inflammatory cells either in vessel lumina or in the perivascular infiltrate. The skin biopsy taken at 6 d showed some foci of persistent perivascular inflammatory infiltrate, but there was no staining with H4/18 in endothelium. Control antibodies failed to reproduce the endothelial staining obtained with H4/18. Anti-vWF antibody stained microvascular endothelium in all sections at all time intervals.

Pathological Tissues. Our initial survey of pathological tissues with the H4/18 antibody has shown specific labeling of vascular endothelium in several clinicopathologic settings. There was extensive staining in a lymph node of a patient with angioimmunoblastic lymphadenopathy with developing T cell lymphoma (11). The reaction product was exclusively in the endothelium (Fig. 3), most prominently in the hyperplastic venules characteristic of this entity. There was no staining of the highly pleomorphic mononuclear infiltrate within the lymph node. No similar distribution of staining was seen with other mAbs used to immunophenotype this patient’s lymph node. The endothelium was also reactive in lymph nodes of two cases of acute granulomatous lymphadenitis (consistent with cat scratch disease) and in lymphocyte-rich thyroiditis (one case), hyperplastic tonsillitis (three cases); and active inflammatory dermatitis (2 cases). Endothelial staining was also observed in lymph nodes or skin of eight patients with Hodgkin’s or T cell lymphoma; the staining was strongest in the hyperplastic vessels which were often present in these conditions. In contrast, we have thus far found minimal or no staining in lymph nodes with B cell lymphoma (four cases), dermatopathic lymphadenitis (three cases), chronic sarcoid granuloma (three cases), and in renal allograft rejection (eight cases), foreign-body granuloma (one case), chronic pneumonitis (two cases), viral hepatitis (two cases), and around burn wounds (three cases). In two cases of appendicitis, endothelial staining was noted in vessels surrounded by inflammatory infiltrate.

Discussion

In this study we have shown that the murine mAb H4/18, which binds an antigen induced in cultured endothelium by IL-1, also recognizes an endothelial
molecule induced in vivo by DHR in human skin. The antigen can be also
detected by immunocytochemical techniques in pathological tissues mostly in
clinical settings of immunological activation. To our knowledge, this is the only
reported endothelial-specific mAb that fails to react with normal endothelium,
but identifies activated endothelium in vivo.

The immunohistochemical results reported here are consistent with the kinet-
ics of H4/18 binding in vitro. H4/18 uniformly fails to bind normal endothelial
cells, or normal and activated leukocytes in situ, as is the case in vitro. The IL-
1-induced binding in culture is transient; in the induced DHR reactions in the
skin, H4/18 staining disappeared as the lesions faded. Our preliminary screening
of pathological tissue also suggests the antigen is transiently inducible by media-
tors. The staining was focal, and was most prominent in hyperplastic endothelium
in settings of inflammatory or neoplastic reactions associated with activated
lymphocytes and macrophages.

Although evidence for the active role of the endothelial cell in inflammation
and the importance of inducible endothelium functions has come from recent
work, the notion of endothelial cell activation is a relatively old one. Early light
and electron microscopic studies of DHR described plump, hypertrophied en-
dotheIium with increased numbers of intracellular organelles, and it was sug-
gested that the endothelium was activated in these reactions (12). It now seems
likely that these changes of activation reflect some of the alterations in structure,
function, and growth induced in endothelium by specific lymphokines and
monokines. The studies reported here support the concept of endothelial acti-
vation and provide a useful marker for its further investigation in vivo.

Summary

We used a murine mAb, H4/18, raised by immunization with IL-1-treated
human umbilical vein endothelial cell cultures, to localize an endothelial activa-
tion antigen in induced human delayed hypersensitivity reactions (DHR) and in
pathological tissues. We used streptococcus varidase to elicit DHR in human skin
and we examined sequential skin biopsies with the immunoperoxidase technique.
There was no staining for H4/18 binding antigen in normal endothelium of skin
and other tissues; strong positive staining, localized to vascular endothelium, was
seen at 16 and 23 h but disappeared by 6 d, when the DHR had faded. H4/18
binding antigen, also confined to endothelium, was detected in lymph nodes,
skin, and other tissues exhibiting immune/inflammatory reactions. The studies
indicate that H4/18 is a useful marker for activated endothelium in vivo and
they support the relevance of in vitro studies on inducible endothelial cell
functions.

Most of the immunohistochemical studies reported here were performed in the Depart-
ment of Pathology, University of Leiden, The Netherlands. We thank the staff for
invaluable help and useful discussions, and particularly Dr. R. Willemze, Dr. P. Kluin, A.
Dijkstra, E. Dreef, and J. C. van Rijn.

Received for publication 28 April 1986.
References

1. Bevilacqua, M. P., J. S. Pober, G. R. Majeau, R. S. Cotran, and M. A. Gimbrone, Jr. 1984. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 160:618.

2. Bevilacqua, M. P., J. S. Pober, G. R. Majeau, W. Fiers, R. S. Cotran, and M. A. Gimbrone, Jr. 1986. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc. Natl. Acad. Sci. USA. 83:4533.

3. Bevilacqua, M. P., J. S. Pober, M. E. Wheeler, R. S. Cotran and M. A. Gimbrone, Jr. 1985. Interleukin-1 acts on cultured human vascular endothelium to increase adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J. Clin. Invest. 76:2003.

4. Bevilacqua, M. P., J. S. Pober, M. E. Wheeler, R. S. Cotran, and M. A. Gimbrone, Jr. 1985. Interleukin 1 activation of vascular endothelium: effects on procoagulant activity and leukocyte adhesion. Am. J. Pathol. 121:393.

5. Schleimer, R. P., and B. K. Rutledge. 1986. Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters. J. Immunol. 136:649.

6. Gamble, J. R., J. M. Harlan, S. J. Klebanoff, and M. A. Vadas. 1985. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl. Acad. Sci. USA. 82:8667.

7. Pober, J. S., M. P. Bevilacqua, D. L. Mendrick, L. A. Lapierre, W. Fiers, and M. A. Gimbrone, Jr. 1986. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J. Immunol. 136:1680.

8. Parham, P. 1983. On the fragmentation of monoclonal IgG, IgG2a, and IgG2b from Balb/c mice. J. Immunol. 131:2895.

9. Bhan, A. K. 1984. Application of monoclonal antibodies to tissue diagnosis. In Advances in Histochemistry. R. A. DeLellis, editor. Masson Publishing USA, Inc., New York. 1–29.

10. Hancock, W. W., and R. C. Atkins. 1986. Immunohistological studies with monoclonal antibodies. In Immunochemical Techniques. G. de Sabato, J. J. Langone, and L. van Vunakis, editors. Academic Press, Inc., Orlando, FL. 828–848.

11. Weiss, L. M., J. G. Strickler, R. F. Dorfman, S. J. Horning, R. A. Warnke, and J. Sklar. 1986. Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Am. J. Pathol. 122:392.

12. Willms-Kretschmer, K., M. H. Flax, and R. S. Cotran. 1967. The fine structure of the vascular response to hapten-specific delayed hypersensitivity and contact dermatitis. Lab. Invest. 1:334.